Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Recruiting 2Not yet recruiting 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Breast Neoplasms 3092Neoplasms 2436Carcinoma, Non-Small-Cell Lung 1863Prostatic Neoplasms 1617Colorectal Neoplasms 1422Lung Neoplasms 1292Multiple Myeloma 927Neoplasm Metastasis 919Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 847Ovarian Neoplasms 799Melanoma 783Carcinoma, Hepatocellular 736Stomach Neoplasms 639Brain Neoplasms 635Recurrence 633Squamous Cell Carcinoma of Head and Neck 630Head and Neck Neoplasms 609Glioblastoma 566Lymphoma 539Uterine Cervical Neoplasms 537Triple Negative Breast Neoplasms 504Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 497Hematologic Neoplasms 462Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 441Lymphoma, Non-Hodgkin 435Sarcoma 434

Interventions

Specimen Handling 1Medical Marijuana 1Gemcitabine 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Pancreatic Cancer Non-resectable × 1 year × Clear all
NCT07575191 2026-05-08

Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

Smartwise Sweden AB

Phase 1/2 Not yet recruiting
9 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT07386704 2026-02-04

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Peking University First Hospital

Phase 2 Enrolling by invitation
30 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT07302841 2025-12-24

Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 4 Not yet recruiting
28 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT07271823 2025-12-09

Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer

Zhejiang Cancer Hospital

Active not recruiting
100 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT06605430 2025-07-29

CanPan-C

HealthPartners Institute

Phase 2 Recruiting
64 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT06937996 2025-06-17

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

Englewood Hospital and Medical Center

Recruiting
25 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡